Summit: Updated HARMONi OS Analysis Shows HR 0.76 for Ivonescimab Across Global Population

Summit reported updated HARMONi overall survival results showing a hazard ratio of 0.76 in the full population and western subgroup.

Key Highlights:

• Updated OS analysis (data cutoff June 2026) shows hazard ratio 0.76 in both the intent-to-treat population and western patients, consistent with Asian results.
• Western median follow-up increased to 23.2 months (Asian median follow-up 32.7 months), improving western subgroup HR over prior cuts.
• Ivonescimab plus chemotherapy maintained an acceptable, manageable safety profile with no new safety signals noted.
• Detailed data have been shared with the FDA and are planned for presentation at an upcoming medical conference ahead of the BLA PDUFA date November 14, 2026.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.